NotoginsenosideFt1 is a saponin found in Panax notoginseng. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8+ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca2+ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y12 receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance[1][2][3][4][5][6][7][8].
Promoted PI3K, AKT, mTOR, c-Raf, MEK1/2 and ERK1/2 phosphorylation.
Promoted HIF-1α translocation from the cytoplasm to the nucleus in a time-dependent manner.
Significantly increased p-eNOS, but no significant change in total eNOS expression; eNOS expression was almost undetectable in the endothelial removal group.
Increased Akt phosphorylation and ERK1/2 phosphorylation.
Increased the levels of p-GR (Ser211) and p-ERβ (Ser87) in the endothelial layer.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Matrigel plug assay established in Balb/c nude mice (8 weeks old)[1]
Dosage:
1, 5 and 25 μM with Heparin (HY-17567) in Matrigel
Administration:
Intraperitoneal injection (i.p.), single dose
Result:
Formed of a functional vasculature inside the Matrigel.
Increased the hemoglobin content in a dose-dependent manner.
Revealed a dose-dependent increase in staining with the blood vessel endothelial cell marker CD-31 Matrigels with more enlarged and more blood vessels.
Animal Model:
Ear wound healing assay established in Balb/c nude mice (8 weeks old)[1]
Dosage:
0.25 mg/kg, 2.5 mg/kg or 25 mg/kg
Administration:
Intraperitoneal injection (i.p.), every other day for 28 days
Result:
Significantly reduced the diameter of the wound, and more new blood vessels could be observed at the wound edge.
Significantly upregulated the expression of VEGF mRNA.
No significant difference in the weight changes of the mice in each group.
Animal Model:
Diet-induced obesity model established in Tgr5 -/- mice, Cyp27a1-/- mice and wild-type mice[5]
Dosage:
50 and 100 mg/100 g diet
Administration:
Oral administration (p.o.) with diet, for 6 weeks
Result:
Reduced the weight gain of mice, significantly decreased the diameter of fat cells, and reduced the deposition of lipid droplets in the liver.
Reduced fasting metabolic parameters, lowered blood sugar, improved insulin resistance index (HOMA-IR) and enhanced insulin sensitivity.
Increased energy digestion and improved cold tolerance.
Upregulated Cyp7a1 and Cyp27a1 mRNA in the liver and downregulated Fgf15 mRNA in the ileum.
Increased Ucp1 expression in BAT and iWAT, and upregulated genes such as Pgc1a and Prdm16.
Increased PKA substrate phosphorylation, HSL phosphorylation, and serum glycerol levels.
Animal Model:
HepG2 xenograft tumor model established in adult male mice[6]
Dosage:
25 and 50 mg/kg
Administration:
Oral administration (p.o.), once daily for 3 weeks
Result:
Significantly reduced tumor volume and weight.
No significant weight loss caused, and no obvious pathological changes found in major organs.
Reduced KRAS, ERK1/2, c-Fos, and JUND proteins levels.
Animal Model:
MC38 or CT26 -induced CRC model established in C57BL/6J and Balb/c mice, male, SPF grade, aged 6-8 weeks, and weighing 18 g[7]
Dosage:
10 and 30 mg/kg
Administration:
Intraperitoneal injection (i.p.), once daily for 24 days
Result:
Significantly inhibited tumor growth at 30 mg/kg.
No obvious weight loss, no obvious pathological changes in major organs such as liver and kidney.
Significantly increased the proportion of CD8+ T cells in tumors.
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。
可选溶剂
浓度溶剂体积质量
1 mg
5 mg
10 mg
25 mg
DMSO
1 mM
1.0904 mL
5.4518 mL
10.9036 mL
27.2589 mL
5 mM
0.2181 mL
1.0904 mL
2.1807 mL
5.4518 mL
10 mM
0.1090 mL
0.5452 mL
1.0904 mL
2.7259 mL
15 mM
0.0727 mL
0.3635 mL
0.7269 mL
1.8173 mL
20 mM
0.0545 mL
0.2726 mL
0.5452 mL
1.3629 mL
25 mM
0.0436 mL
0.2181 mL
0.4361 mL
1.0904 mL
30 mM
0.0363 mL
0.1817 mL
0.3635 mL
0.9086 mL
40 mM
0.0273 mL
0.1363 mL
0.2726 mL
0.6815 mL
50 mM
0.0218 mL
0.1090 mL
0.2181 mL
0.5452 mL
60 mM
0.0182 mL
0.0909 mL
0.1817 mL
0.4543 mL
80 mM
0.0136 mL
0.0681 mL
0.1363 mL
0.3407 mL
100 mM
0.0109 mL
0.0545 mL
0.1090 mL
0.2726 mL
Help & FAQs
Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Powered by Bioz
